Clinical Trial Update: Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating the efficacy and safety of GSK2190915 given once daily for asthma; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK2190915

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2017-09-06